Key Events This Week
21 Sep: Parmax Pharma Ltd hits new 52-week and all-time high at Rs.136.40
22 Sep: Stock price remains steady at Rs.136.40 amid Sensex decline
23 Sep: Price unchanged at Rs.136.40 as Sensex gains 0.56%
24 Sep: Stock price flat at Rs.136.40 despite Sensex falling 1.62%
25 Sep: Week closes at Rs.136.40 with Sensex modestly up 0.18%
21 September 2026: New 52-Week and All-Time High at Rs.136.40
Parmax Pharma Ltd achieved a significant milestone on 21 September 2026 by reaching a new 52-week and all-time high closing price of Rs.136.40. This represented a 1.00% increase from the previous close of Rs.135.05 and outperformed the Sensex, which rose 0.46% on the day to close at 35,787.64. The stock’s rally is notable given its micro-cap status and the broader market’s cautious tone.
Technical indicators strongly supported this upward momentum. The stock traded above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling robust buying interest. Weekly and monthly MACD, Bollinger Bands, KST oscillator, and Dow Theory indicators were bullish, although the monthly RSI suggested some medium-term caution. The stock’s delivery volume increased by 57.45% compared to the five-day average, indicating heightened investor participation.
Despite the strong price performance, Parmax Pharma remains a loss-making company with negative valuation multiples such as EV/EBITDA at -41.51 times and EV/EBIT at -27.60 times. The price-to-book ratio is also negative at -15.11 times. These metrics reflect ongoing financial challenges, although recent six-month net sales grew by 70.31% to ₹11.53 crores and profit after tax rose to ₹1.62 crores, signalling some operational improvement.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
22 to 25 September 2026: Price Stability Amid Market Volatility
Following the peak on 21 September, Parmax Pharma’s stock price remained steady at Rs.136.40 for the remainder of the week, despite notable fluctuations in the Sensex. On 22 September, the Sensex declined by 0.32% to 35,672.04, while the stock held its ground with no price change. The following day, the benchmark index rebounded by 0.56%, yet Parmax Pharma’s price remained unchanged.
On 24 September, the Sensex experienced a sharp decline of 1.62%, closing at 35,291.38, but the stock price again showed resilience by maintaining Rs.136.40. The week concluded on 25 September with a modest Sensex gain of 0.18%, and Parmax Pharma closed flat at Rs.136.40. This price stability amid broader market volatility suggests a consolidation phase after the recent rally.
Volume remained consistent at 3,917 shares traded daily, with no additional price movement, indicating a balance between buying and selling pressures. The stock’s Mojo Score stands at 46.0 with a ‘Sell’ grade, upgraded from ‘Strong Sell’ earlier in August, reflecting a cautious but improving market perception.
Weekly Price Performance Comparison
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-21 | Rs.136.40 | +1.00% | 35,787.64 | +0.46% |
| 2026-09-22 | Rs.136.40 | 0.00% | 35,672.04 | -0.32% |
| 2026-09-23 | Rs.136.40 | 0.00% | 35,870.78 | +0.56% |
| 2026-09-24 | Rs.136.40 | 0.00% | 35,291.38 | -1.62% |
| 2026-09-25 | Rs.136.40 | 0.00% | 35,353.29 | +0.18% |
Key Takeaways from the Week
Positive Signals: Parmax Pharma’s attainment of a new 52-week and all-time high at Rs.136.40 underscores strong technical momentum and investor interest. The stock’s sustained trading above all major moving averages and bullish MACD, Bollinger Bands, and KST indicators support a positive trend. The recent upgrade in Mojo Grade from ‘Strong Sell’ to ‘Sell’ indicates improving fundamentals or market sentiment. Additionally, the company’s six-month net sales growth of 70.31% and PAT increase to ₹1.62 crores highlight operational progress.
Cautionary Notes: Despite price strength, the stock’s valuation multiples remain negative due to ongoing losses, with EV/EBITDA and EV/EBIT ratios deeply in the red. The monthly RSI’s bearish signal suggests potential medium-term momentum weakening. The stock’s micro-cap status entails higher volatility and risk. Furthermore, the reliance on non-operating income, which constitutes 94.55% of profit before tax, warrants scrutiny regarding earnings quality. The flat price movement from 22 to 25 September amid Sensex volatility may indicate consolidation or investor indecision.
Holding Parmax Pharma Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion
Parmax Pharma Ltd’s performance during the week ending 25 September 2026 was characterised by a landmark price peak and subsequent price stability amid a volatile market backdrop. The stock’s 1.00% weekly gain contrasted with the Sensex’s 0.76% decline, reflecting relative strength in a micro-cap pharmaceutical entity. While technical indicators and recent sales growth provide encouraging signs, the company’s negative valuation multiples and reliance on non-operating income highlight ongoing financial challenges. Investors should weigh these factors carefully as the stock consolidates near its all-time high.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
